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This study aimed to do a review of the literature regarding the use of topic iodine and/or compounds in
the treatment of chronic wounds. The clinical trials were searched in the Cochrane database. Fourteen (58.3%)
among 24 studies fulfilled the inclusion criteria. The articles were analyzed regarding journal and study
characteristics and classified into three groups: Iodine versus other topic agents (7/ 50%); Iodine versus
different dressings (6/ 42.9%); Iodine versus without Iodine (1/ 7.1%). Favorable results for the use of Iodine
or similar product occurred in 50% of the analyzed studies. Six out of 8 trials showed favorable results for
healing and infection prevention/ treatment; 4 out of 5 were not favorable when the healing objective was
investigated and 1 study for infection treatment showed no favorable result.
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USO DE YODO TÓPICO Y/O COMPUESTOS EN HERIDAS CRÓNICAS: REVISIÓN DE LA
LITERATURA
La investigación trata de una revisión de la literatura a cerca de la utilización del yodo tópico y/o
compuestos en el tratamiento de las heridas crónicas. Se buscaran los ensayos clínicos en el Cochrane. Catorce
(n=24) publicaciones estaban de acuerdo con los criterios de inclusión, y fueran analizadas según las
características de las revistas y ensayos y clasificadas como: yodo versus otros agentes tópicos (7/ 50%);
yodo versus curativos (6/ 42,9%) y yodo versus sin yodo (1/ 7,1%). Fueran obtenidos resultados favorables a
la utilización del yodo y/o compuestos en 50% de los artículos analizados. Cuanto a las tendencias de los
resultados, 6 de 8 publicaciones, a cerca de la de cicatrización de las heridas y prevención de infección, fueran
favorables; 4 de 5 fueran no favorables solamente para la cicatrización, y el resultado del único trabajo con
indicación del uso para tratamiento de infección de herida fue no favorable.
DESCRIPTORES: compuestos de yodo; cicatrización de heridas; literatura de revisión
USO DE IODÓFORO TÓPICO EM FERIDAS CRÔNICAS: REVISÃO DA LITERATURA
Trata-se de revisão de literatura relacionada ao uso de iodóforos tópicos no tratamento de feridas crônicas.
Os ensaios clínicos foram localizados por meio da Base de Dados Cochrane de Revisões Sistemáticas e Registro
Cochrane Central de Ensayos Controlados. Quatorze (58,3%), dentre 24 artigos, atenderam os critérios de inclusão,
analisados quanto às características dos periódicos e dos estudos e classificados em três grupos: iodóforo versus
outros agentes tópicos (7 ou 50%); iodóforo versus coberturas (6 ou 42,9%) e iodóforo versus sem iodóforo (1 ou
7,1%). Resultados favoráveis à utilização dos iodóforos ocorreram em 50% dos artigos analisados. Quanto às
tendências dos resultados, seis, dentre oito artigos, que tratavam de cicatrização de feridas e prevenção de
infecção, foram favoráveis; quatro, dentre cinco, foram desfavoráveis somente para a cicatrização e no único
ensaio em que houve indicação do seu uso para tratamento de infecção de ferida o resultado foi desfavorável.
DESCRITORES: compostos de iodo; cicatrização de feridas; literatura de revisão
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INTRODUCTION
The development of antiseptics is related to
the history of wound treatment. Their basic objectives
are to reduce risks and prevent or reduce infectious
complications.
Antiseptics are hypoallergic substances, of low
causticity, which possess lethal or inhibiting action of
microbial reproduction, for application on skin and
mucous tissues(1).
For more than a century, iodine was
considered one of the most efficacious antiseptics.
Although discovered in 1812 by the French scientist
Dijon Bernad Courtors, it was only denominated iodine
in 1814 by Gay Loussac. The word originates from
the Greek word ioidés and refers to the purple color
of its vapor(2). It was officially recognized by the United
States Pharmacopea in 1830. Some years later, in
1839, the first report was made of its specific use in
wounds.
Despite the antimicrobial advantages
obtained through its use, several disadvantages were
observed in its clinical application(2), making
pharmaceutical industries develop new research and
formulations that led to the production of iodophors.
The term iodophor literally means iodine
carrier. Iodophors consist of a stable combination of
molecular iodine or triiodide with a transporter of high
molecular weight. In aqueous solution, iodophors free
iodine molecules, as found in pure solutions. The most
known iodophor is the polyvinylpyrrolidone, a complex
of 1-vinyl-2-polymers-pyrrolidone with iodine (PVP-
I)(2-3).
For many authors and in the specific Brazilian
legislation, the use of PVP-I on healthy skin is a
consensus, especially in the preoperative phase(4).
However, authors show different and controversial
results(5) for topical wound treatment.
Because of all this controversy and
considering the indiscriminate use of antiseptics by
several health professionals, especially iodinated
formulations, whether due to a lack of technical
knowledge, ignorance or devaluation of potential
environmental and direct toxicological effects to
patients and professional agents, we decided to
elaborate this study, aiming to carry out a literature
review related to the use of iodophors in chronic wound
treatment.
METHOD
The literature review is considered an ample
and critical revision of the most important specialized
studies about a specific theme, whose specific aim
depends on the reviewer’s role, for example,
acquisition of knowledge on a topic, preparation of
critiques about existing nursing practices and
recommendations for innovations, development of
clinical protocols and interventions based on research
in order to improve clinical practice, among others(6).
It is also considered indispensable in all steps of the
quantitative research process(7).
There were seven phases that guided the
procedures in this study, similar to those used in the
systematic literature review process, ranging from the
research question, definition of inclusion criteria and
search strategies, search per se, selection of obtained
studies and critical assessment of the studies, to the
collection and synthesis of specific collected data(6). In
this study, the seventh phase was modified and
developed through the analysis of scope,
methodological design, study results and conclusions(8).
Given that the literature that involves the study
of iodophors in chronic wounds - as the object of this
research - is vast and reasonably old, we decided to
include all clinical trial research articles published in
journals indexed in the Cochrane Systematic Reviews
database and Cochrane Central Register of Controlled
Trials in the study sample. The decision to use only
this database was because it contains a significant
quantity of controlled clinical trials, considered sufficient
to meet the study objective.
For the inclusion and analysis of the articles,
the following criteria were established: clinical trials
published in full text in English, Portuguese and
Spanish. Articles related to mucous tissues were
excluded, as well as those written in other languages,
even with the abstract in English, and also editorials,
letters and works published in the form of abstracts.
The bibliographic review was performed
electronically from July, 2003 to June, 2004. The
access to the Cochrane database was done through
the Cochrane library*, available on the BIREME -
Medical Regional Library (http://www.bireme.br)
website, using the following grouped descriptors, in
English: iodine, acute wound, treatment, healing,
infection, surgery, surgical.
* Brazilian Cochrane Center - Brazilian section of the Cochrane Collaboration - updated collection of information sources on evidence-based medicine, for
health care providers as well as professionals active in research, education and public administration, at all levels.
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For data collection, a specific instrument was
used, composed of: journal data (name, year, issue,
number, original language, country); researcher data
(quantity, name(s), profession(s) and place of
activity); and article data (title; year and research
site; case identification; scope; methodological design;
results and conclusions).
RESULTS
Among 24 full text articles, 14 met the inclusion
criteria and composed the research sample.
The results show that the first publication on
the use of iodophors in chronic wounds occurred in 1980
and that the largest number of publications appeared in
the 1980s (9/64.3%). All articles analyzed were written
in English. The countries where the studies were
performed are mostly European (9/64.2%), especially
Sweden (3), Finland, England and Germany (with two
studies in each of these countries). The trials analyzed
were published in 12 different journals. Two of them -
Acta Chirurgica Scandinavica/ Supplementum and
Dermatology - published two articles each, that is, the
largest number of articles considering isolated journals.
The United States and England were leaders regarding
the origin of the periodicals (four in each) the articles
were published in. Regarding the authors of the trials,
the clear presence of physicians stood out in all studies.
The majority of publications (71.4%) was about patients
with vasculogenic ulcers, of venous origin.
For the quantitative analysis, the studies were
initially classified according to the product used for
comparison with the iodophor: Group I - Iodophors x
Other Topical Agents - 7 articles (50%); Group II -
Iodophors x Dressings - 6 articles (42.9%); Group
III - Iodophors x no Iodophors - 1 article (7.1%).
Regarding the formulation of the iodophors
used in the clinical trials, Cadexomer-iodine (CI) 0.9%
was the most frequent (57.2%). PVP-I at 5% solution
was used in 14.3% of the studies. Varied solutions used
for wound cleansing, with physiological solution as the
most frequently used (50%). The solutions used in this
procedure were not described in four of the studies.
The use of iodophors in chronic wounds met
two main objectives: infection prevention/treatment
(1 study) and wound healing (5 studies). For the
remaining 8 articles, both objectives were proposed.
From the 14 studies analyzed, half (seven)
were favorable to the use of iodophors in chronic
wounds. Five were performed on venous ulcers in
the inferior limbs and two on patients with skin grafts.
In addition, six out of eight investigations that tested
both objectives - infection prevention and/or
treatment and wound healing - showed favorable
results. In summary, positive results were found in
only one of the five studies whose objective was to
perform isolated evaluation of healing. The largest
number of publications with unfavorable results
regarding the use of iodophors occurred in 1987 (2).
After the first half of the 1990s, all results of these
studies were favorable to the use of iodophors in
chronic wound care.
DISCUSSION
Iodophors are antiseptic of wide antimicrobial
range, available in several formulations. Several
studies have been developed to investigate their
efficacy, in different formulations and presentations,
for wound infection prevention or treatment, as well
as their influence in the healing process, comparing
them with other products used in this therapeutic
procedure or with no products. Nevertheless, the
topical use of iodophors is still controversial.
Therefore, this study proposed to review
clinical trials related to the use of iodophors in the
topical treatment of chronic wounds, evaluating the
objectives and methods, as well as the results and
conclusions, whether favorable or not, with a view to
establishing tendencies for its adoption in these clinical
conditions.
A total of 14 clinical trials about the use of
iodophors in chronic wound treatment for infection
prevention or treatment or to assess its influence in
the healing process were included in this review. The
studies were performed in several countries, especially
European, while no research had been developed in
Brazil or any other South American country.
A total of seven clinical trials compared the
use of the PVP-I iodophor solution or CI with other
topical agents in chronic wounds (Group I), considering
the healing or reduction of wound size(9-15).
In one of the studies*(9-10), at the end of eight
weeks, 65% of patients in the CI Group showed
* The same study was published in two different journals (references 9 and 10).
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completely healed venous ulcers, against 50% in the
Dextranomer Group (D). Although the authors
observed higher wound reduction levels among CI
patients, no statistically significant difference was
found, concluding that the use of PVP-I was not
superior in the treatment of venous ulcers. In addition,
in another study(11), the authors reached similar
conclusions, since no significant reduction in ulcer size
was observed in the first six weeks of treatment with
CI or D, according to statistical tests.
As opposed to these results, when studying the
use of PVP-I compared to D, the author(12) demonstrated
the superiority of Dextranomer regarding the smaller
average time for ulcer cleansing - wound with no
exsudate, pus or devitalized tissue - reduction of
microbial load and formation of granulated tissue and
epithelization, with a statistically significant difference.
Comparing CI with other conventional
treatments, the authors(13) achieved similar results to
those found in previous studies(9-11), with no significant
difference between the groups regarding the reduction
of venous ulcer area sizes. However, a significant
reduction of pain was found during the first weeks of
treatment with CI.
Nevertheless, in a similar study(14), results
favorable to the use of CI were described. After eight
weeks of treatment, 13 ulcers of the CI group were
healed, showing a statistically significant difference
with the Group of Conventional Treatments - TC (which
included different agents). In the fourth week of
treatment, the CI Group was also significantly more
effective than the TC in several evaluated criteria:
ulcer size, edema, erythema, exsudate, odor, pus and
pain. It is interesting to observe that, in the fourth
week, the patients had the option to change the
treatment and this change was also significant in favor
of the group CI.
For other chronic ulcers, the trial(15) compared
the topical use of Silver Sulfadiazine (SS), PVP-I and
physiological solution (PS), considering the reduction
of the microbial load and of the size of the pressure
ulcer. Its results showed a significant difference in
favor of the group that used SS for both objectives.
In the comparative analysis of iodophors with
different dressings (Group II), researchers from the
University der Rohr(16-17) compared the use of a new
formulation of PVP-I - liposomal hydrogel - and of a
dressing impregnated with chlorhexidine (C) in patients
after skin grafting. One of the relevant criteria used
was the loss of the graft, which occurred in only one
patient in the PVP-I Group, in comparison with five in
the C Group (p=0.01). The level of re-epithelization
and the quality of tissue in the healing process were
also evaluated and were significantly higher in the
PVP-I Group (p<0.04). The use of PVP-I liposomal
hydrogel also showed higher efficacy in local and
systemic tolerability, without significantly altering the
thyroidal hormones, confirming the efficacy of its use.
In two other studies(18-19), the use of iodinated
solutions (CI or PVP-I, respectively) in venous ulcer
treatment was compared to the use of coverings:
hydrocoloid dressings (HD) in both, besides the use of
paraffin gauze (PG) in the first study. In the first
research(18), the reduction of the wound and quantity of
slough were analyzed and both criteria were significantly
higher among patients of the CI group in comparison
with the other two groups (HD and PG). Regarding the
impact on the thyroidal function, there was no glandular
dysfunction. Costs were similar between groups CI, HD
and PG, although the frequency of dressing changes
was higher in the CI group. The other study(19), which
used the patients themselves as controls, also showed
favorable results regarding the use of PVP-I associated
to HD in comparison with isolated treatment with HD.
Similarly to a previous study, these studies concluded
that the PVP-I contributed to the acceleration in the
healing level of the venous ulcers, besides diminishing
the microbial load.
Other authors(20-21) also presented favorable
conclusions in their studies regarding the use of CI in
the treatment of venous ulcers compared to several
conventional treatments (TC), when considering
infection healing and prevention, through the reduction
of microbial load, besides the absence of significant
alterations in the thyroidal hormones.
Only one clinical trial evaluated the isolated
efficacy of PVP-I (Group III) in the treatment of post
cardiac surgical mediastinitis(22). Its results did not show
significant differences between the groups (with and
without PVP-I) regarding the level of mortality and time
of hospital treatment, concluding that the use of
irrigation with PVP-I does not present benefits in this
treatment. The authors suggest that better results are
obtained through early diagnosis, debridement and
wound re-suture, combined with systemic antibiotics.
Aiming to establish the tendencies in the use
of iodophors in chronic wounds, it was verified that,
in half of the studies, the authors were favorable to
its use, especially in those studies in which the
iodophors were compared to several types of
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dressings. In addition, half of the studies that involved
patients with venous ulcers and the two trials with
skin grafting appointed favorable results for the use
of iodophors, independently of the objective to be
tested. However, the studies with patients with infected
surgical wounds and pressure ulcers were unfavorable
to the use of the iodophors.
Despite the use of clinical trials, some
considerations should be described. In some of the
studies, the use of different types of products(13-14) was
observed, which composed the TC, with different
influences on the tissue healing process. In addition,
in some of them, different products were used for
cleansing or for the maintenance of the wound(12,20-21),
which could cause interaction with the topical products
used previously or afterwards, or yet distinct influence
on the healing process. On the other hand, half the
clinical trials did not describe the randomization process
for the composition of treatment groups(10-12,14,18-20). It
is also important to consider the restricted size of the
sample in the studies analyzed.
CONCLUSIONS
These investigation results did not allow for
a definition regarding the tendencies of iodophor use
in topical chronic wound therapy, especially due to
the number of studies that composed it and the
impossibility of performing the meta-analysis because
of the different methods employed, as well as the
lack of relevant information.
The search for new formulations of iodophors,
more effective and with lesser adverse effects,
probably composes one of the alternatives for future
research, as a recent study*(16-17) indicates favorable
and promising results for the use of PVP-I liposomal
hydrogel in wound healing. Besides, the development
of new experimental, controlled and randomized
studies, involving larger samples will add to the
evidences available here, with a view to a more
precise and safe determination of the use of these
products in chronic wounds, in terms of infection
prevention and treatment and acceleration of the tissue
healing process.
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